The abstract is read at the publisher; the summary is JClub's.
In a retrospective cohort of 151 patients with immune-mediated bone marrow failure syndromes, salvage immunosuppressive therapy—including sirolimus—produced significant response rates with lineage- and disease-state–dependent efficacy.
- Why it matters: First- and second-line immunosuppressive therapy often relapses or fails, and refractory/relapsed settings lack clinical trials to guide alternative treatment choices.
- What they did: The study retrospectively assessed clinical responses to salvage IST options—sirolimus, tofacitinib, subcutaneous abatacept, and alemtuzumab—in aplastic anemia, pure red cell aplasia, large granular lymphocytic leukemia, and other rare hypoproliferative BMFS.
- The result: Responses differed by affected lineage and whether disease was relapsed or refractory, and durable responses were observed in clinically difficult cases, supporting the need for trials of alternative agents.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.